Astria Therapeutics (ATXS) Projected to Post Quarterly Earnings on Monday

Key Points

• Astria Therapeutics is set to release its Q2 2025 earnings on August 11th, with analysts expecting a loss of ($0.61) per share.
• The company's stock is currently priced at $6.61, and the average price target among analysts is $29.00, indicating positive sentiment towards future performance.
• Institutional investors hold approximately 98.98% of Astria Therapeutics' shares, with Jane Street Group LLC recently increasing its stake by 317.3%.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, analysts expect Astria Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Astria Therapeutics Stock Performance

Shares of ATXS traded down $0.39 on Friday, hitting $6.28. 177,444 shares of the stock traded hands, compared to its average volume of 213,425. The company has a market capitalization of $354.38 million, a PE ratio of -3.36 and a beta of 0.48. The business has a 50 day simple moving average of $6.08 and a 200 day simple moving average of $5.79. Astria Therapeutics has a one year low of $3.56 and a one year high of $12.92.

Institutional Investors Weigh In On Astria Therapeutics

An institutional investor recently raised its position in Astria Therapeutics stock. Jane Street Group LLC increased its stake in Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 317.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 108,898 shares of the biotechnology company's stock after purchasing an additional 82,805 shares during the quarter. Jane Street Group LLC owned 0.19% of Astria Therapeutics worth $582,000 at the end of the most recent quarter. Institutional investors and hedge funds own 98.98% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ATXS shares. Cantor Fitzgerald reissued an "overweight" rating and set a $47.00 price target on shares of Astria Therapeutics in a research report on Wednesday, May 14th. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Friday, June 13th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Astria Therapeutics currently has an average rating of "Buy" and a consensus target price of $29.00.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.